COSMO Pharmaceuticals SA Stock Swiss Exchange
Equities
LU1202320294
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CHF | - |
Apr. 26 | Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 | CI |
Apr. 25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
Sales 2023 | 96.72M 103M 94.5M | Sales 2024 * | 262M 280M 256M | Capitalization | 1.18B 1.26B 1.15B |
---|---|---|---|---|---|
Net income 2023 | 1M 1.07M 977K | Net income 2024 * | 111M 119M 108M | EV / Sales 2023 | 8.6 x |
Net cash position 2023 | 48.44M 51.79M 47.32M | Net cash position 2024 * | 110M 118M 108M | EV / Sales 2024 * | 4.07 x |
P/E ratio 2023 |
771
x | P/E ratio 2024 * |
10.6
x | Employees | - |
Yield 2023 |
3.65% | Yield 2024 * |
2.86% | Free-Float | 44.49% |
Latest transcript on COSMO Pharmaceuticals SA
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 05-12-31 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Chief Tech/Sci/R&D Officer | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 21-05-27 |
Founder | 69 | 96-12-31 | |
Director/Board Member | 64 | 05-12-31 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |